Diagnostic criteria for mood disorders including major depressive disorder (MDD) largely
ignore biological factors in favor of behavioral symptoms. Compounding this paucity of …

Prevalence rates of depressive disorders in Parkinson's disease (PD) vary widely across
studies, ranging from 2.7% to more than 90%. The aim of this systematic review was to …

In addition to the classic motor symptoms, Parkinson's disease (PD) is associated with a
variety of nonmotor symptoms that significantly reduce quality of life, even in the early stages …

Monoamine oxidase inhibitors (MAO-I) belong to the earliest drugs tried in Parkinson's
disease (PD). They have been used with or without levodopa (L-DOPA). Non-selective MAO …

Parkinson's disease (PD) is the second most common neurodegenerative disease after
Alzheimer's disease. Traditionally, attention has focused on the motor symptomatology of …

A decreased level of brain 5-hydroxytryptamine (5-HT) has been theorized to be a core
pathogenic factor in depression for half a century. The theory arose from clinical …

Abstract Context Depression affects 50–70% of patients with Parkinson's disease resulting
in significant comorbidity, executive dysfunction, and poorer quality of life. Divergent results …

Depression is among the leading causes of disability-adjusted life years in the world 1 and a
serious public health problem among older adults. General medical settings have been …

New criteria for Parkinson's disease‐associated psychosis (PDAP) were recently proposed
by a NINDS‐NIMH working group. We assessed 116 consecutive unselected outpatients …

The pesticide rotenone is widely used to produce Parkinson's disease (PD)-like symptoms in
rodents, but few studies have examined whether rotenone-treated zebrafish can serve as an …